What have we learned about treating lower-risk MDS?

In the first part of a two-video series, Guillermo Garcia-Manero, MD, discusses the treatment of lower-risk myelodysplastic syndromes (MDS) with SOHO young investigators during SOHO 2026.
This video includes the following:

• Goals of therapy in lower-risk MDS
• Treatment approaches based on disease characteristics
• The role of erythropoiesis-stimulating agents and luspatercept
• Results from the MEDALIST and COMMANDS clinical trials
• The importance of early treatment and duration of response
• The potential impact of treatment on survival and disease progression
• Questions surrounding dosing and adverse effects